Search
Search Results
-
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
BackgroundOsimertinib has emerged as an important tool in the treatment of non-small cell lung cancers (NSCLC) with certain activating mutations of...
-
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
BackgroundOsimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients...
-
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Precision cancer medicine has changed the treatment paradigm of patients with non-small cell lung cancer (NSCLC) with specific molecular aberrations....
-
Osimertinib in a patient with end-stage kidney disease not on hemodialysis
Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective in non- small cell lung cancer (NSCLC) with EGFR...
-
Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report
BackgroundOsimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for...
-
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
This is a summary of the original article ‟Overall survival with osimertinib in resected EGFR-mutated NSCLC.ˮ Osimertinib blocks the activity of the...
-
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, an irreversible EGFR-TKI, are important treatments for non-small...
-
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
BackgroundCell-cycle regulators are mutated in approximately 40% of all cancer types and have already been linked to worse outcomes in non-small cell...
-
Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax
BackgroundTo investigate the effects of osimertinib on hepatocellular carcinoma (HCC) and angiogenesis, and its combinatory effects with venetoclax...
-
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
IntroductionDocetaxel is an established standard therapy after osimertinib and platinum-based doublet chemotherapy (Pt-doublet) for locally advanced...
-
Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non–small cell lung cancer and mutated EGFR
PurposeThe ADAURA trial demonstrated the superiority of osimertinib over a placebo with regard to disease-free survival, showing it to be indicated...
-
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
BackgroundAlthough osimertinib is a promising therapeutic agent for advanced epidermal growth factor receptor ( EGFR ) mutation-positive lung cancer,...
-
Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma
ObjectiveAlthough the use of osimertinib can significantly improve the survival time of lung adenocarcinoma (LUAD) patients with epithelial growth...
-
Achievement of pathological complete response with osimertinib for EGFR-mutated lung adenocarcinoma
BackgroundTyrosine-kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) usually provide a potent anti-tumor efficacy with robust...
-
TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer
EGFR tyrosine kinase inhibitors (TKIs) are effective against EGFR -mutated lung cancer, but tumors eventually develop resistance to these drugs....
-
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC)...
-
Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor ( EGFR )-mutated non-small cell lung cancer (NSCLC)....
-
The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib
PurposeGastric metastasis of lung cancer is rare, and the cases of disappearance of gastric metastasis and liver metastasis caused by oxitinib...
